COMPOUND WITH CONFIDENCE: PCCA Membership, $795/month.

Pharmacy compounding's source for clinical information, regulatory updates, and opportunities

THE PCCA BLOG

rss

Stay current on PCCA news and events, market trends, and all things compounding!

Working_with_Compounders_The_FDAs_Recent_Statement_about_Oxitriptan.png

PCCA applauds the FDA for their decision and statement about Oxitriptan, which ensures that patients with BH4 deficiency can continue to receive the compounded medications they need.